(Total Views: 580)
Posted On: 08/26/2020 10:19:50 AM
Post# of 155734
Misiu143,
Remember that placebo in these trials is existing standard of care, so that these patients are not being denied care, just not the additional therpeutic yet to be "proven".
I am pleased that so many companies are digging in and conducting blinded, controlled studies, even when the results are negative. These failed trials add to our knowledge and allow science to advance.
All I heard from the pharmacists and physicians at my local hospital was about tocilizumab. It has been disproven along with the other IL-6 blockers (as Patterson predicted). The good news is that those definitive failures allow resources to pivot toward the next potential therapeutic. CCR5 blockers, VIP, interferon 1, anti-spike mAbs.
Leronlimab should be granted EUA and continue in phase 4. Patients will be saved while additional knowledge gained.
Any FDA moles here listening?
Remember that placebo in these trials is existing standard of care, so that these patients are not being denied care, just not the additional therpeutic yet to be "proven".
I am pleased that so many companies are digging in and conducting blinded, controlled studies, even when the results are negative. These failed trials add to our knowledge and allow science to advance.
All I heard from the pharmacists and physicians at my local hospital was about tocilizumab. It has been disproven along with the other IL-6 blockers (as Patterson predicted). The good news is that those definitive failures allow resources to pivot toward the next potential therapeutic. CCR5 blockers, VIP, interferon 1, anti-spike mAbs.
Leronlimab should be granted EUA and continue in phase 4. Patients will be saved while additional knowledge gained.
Any FDA moles here listening?
(6)
(0)
